期刊文献+

15-PGDH在食管癌中的表达特征及临床意义

Expression and clinical significance of 15- hydroxyprostaglandin dehydrogenase in esophagus cancer
下载PDF
导出
摘要 目的:探讨15.羟基前列腺素脱氢酶(15-PGDH)在食管癌中的表达及其与临床病理特征的关系,并初步评价其意义,方法:随机收集66例食管癌手术病人的癌组织及相应癌旁正常组织,应用免疫组织化学检测15-PGDH表达,进一步分析其表达与食管癌临床病理的相关性.结果:与癌旁正常组织相比,食管癌中15-PGDH的表达水平显著降低甚至缺失.进一步统计分析显示,15-PGDH表达下调与食管癌的TNM分期、分化程度和是否有淋巴结转移密切相关.结论:食管癌中15.PGDH的表达减少或缺失参与了食管癌的发生发展过程,其可以作为反映食管癌恶性生物学行为的一个重要指标. AIM: To investigate the expression and clinical significance of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) protein in esophagus cancer. METHODS: Immunohistochemistry was used to detect the expression of 15-PGDH protein in 66 esophagus cancer tissues and adjacent non-tumor tissues. Statistic analyses were explored to value its relation with the clinicopathological parameters. RESULTS: 15-PGDH expression was found decreased or even absent in esophagus cancer tissues compared with the corresponding non-tumor tissues. Further analysis about its relationship with clinicopathological parameters revealed that the downregulated of 15-PGDH was significantly related with differentiation grade, TNM stage and lymph node metastasis. CON- CLUSION: The expression of 15-PGDH is decreased or even absent in esophagus cancer tissues. The results suggest that 15-PG- DH may be an important indicator in carcinogenesis and progression of esophagus cancer.
出处 《转化医学电子杂志》 2014年第3期7-9,共3页 E-Journal of Translational Medicine
关键词 食管癌 15-羟基前列腺素脱氢酶 临床病理特征 esophagus cancer 15-hydroxyprostaglandin dehydrogenase (15-PGDH) clinical pathologic parameters
  • 相关文献

参考文献11

  • 1Lehtinen L,Vainio P,Wikman H. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer,in-duces epithelial-mesenchymal transition,and promotes cell migration in cultured breast cancer cells[J].Journal of Pathology,2012,(04):674-686.
  • 2Lee HJ,Yang DH,Ryu YM. 15-hydroxyprostaglandin dehy-drogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms[J].Journal of Korean Medical Science,2013,(08):1154-1160.
  • 3Kang PS,Kim JH,Moon OI. Prognostic implication of 15-hydroxyprostaglandin dehydrogenase down-regulation in patients with colorectal cancer[J].J Korean Soc Coloproctol,2012,(05):253-258.
  • 4Liu Z,Wang X,Lu Y. 15-Hydroxyprostaglandin dehydrogen-ase is a tumor suppressor of human gastric cancer[J].CANCER BIOLOGY & THERAPY,2010,(08):780-787.
  • 5Liu Z,Wang X,Lu Y. Expression of 15-PGDH is downregu-lated by COX-2 in gastric cancer[J].CARCINOGENESIS,2008,(06):1219-1227.
  • 6Wang D,Dubois RN. Prostaglandins and cancer[J].GUT,2006,(01):115-122.
  • 7Yan M,Rerko RM,Platzer P. 15-Hydroxyprostaglandin dehy-drogenase,a COX-2 oncogene antagonist,is a TGF-beta-induced suppressor of human gastrointestinal cancers[J].Proceedings of the National Academy of Sciences(USA),2004,(50):17468-17473.
  • 8Swami S,Krishnan AV,Moreno J. Calcitriol and genistein ac-tions to inhibit the prostaglandin pathway:potential combination therapy to treat prostate cancer[J].Journal of Nutrition,2007,(1 Suppl):205S-210S.
  • 9Castro-Sánchez L,Agra N,Llorente Izquierdo C. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellu-lar carcinoma[J].International Journal of Biochemistry and Cell Biology,2013,(11):2501-2511.
  • 10Quidville V,Segond N,Lausson S. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thy-roid carcinoma cell line[J].Prostaglandins & other Lipid Mediators,2006,(1-2):14-30.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部